title: [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].
abstract: OBJECTIVE
  To study changes of cisplatin sensitivity by RNA interfering the excision repair cross-complementing (ERCC) 1 gene in ovarian cancer cell lines.
  
  
  METHODS
  The small interference RNA (siRNA) targeting ERCC1 gene was designed and synthesized by transcription in vitro, and transfected to ovarian cancer cell line ES-2. The mRNA and protein of ERCC1 were evaluated by means of RT-PCR, western blot and immunocytochemistry. The changes of cisplatin sensitivity after interference were examined by methyl thiazolyl tetrazolium (MTT) assay.
  
  
  RESULTS
  In ES-2 cell, the mRNA and protein levels of ERCC1 were dramatically decreased 24, 48 and 72 hours after transfection. The sensitivity to cisplatin of ES-2 cell line was increased by 53.88 times after disturbing the ERCC1 gene.
  
  
  CONCLUSIONS
  The sensitivity to cisplatin of ovarian cancer cell lines ES-2 could be enhanced by RNA interfering ERCC1 gene.
authors.affiliation: Department of Obstetrics and Gynecology, General Hospital of Tianjin Medical University, Tianjin 300052, China.
authors.forename: Guo-yan
authors.initials: GY
authors.lastname: Liu
authors.forename: Quan-xin
authors.initials: QX
authors.lastname: Qu
authors.forename: Ruo-ran
authors.initials: RR
authors.lastname: Mi
authors.forename: Jing
authors.initials: J
authors.lastname: Qi
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D015153:Blotting, Western; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D002945:Cisplatin / Q000494:pharmacology*; D004260:DNA Repair; D004268:DNA-Binding Proteins / Q000235:genetics* / Q000378:metabolism / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm; D004720:Endonucleases / Q000235:genetics* / Q000378:metabolism / Q000502:physiology; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000235:genetics / Q000473:pathology; D034622:RNA Interference; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D034741:RNA, Small Interfering / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection
chemical_list: D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D012333:RNA, Messenger; D034741:RNA, Small Interfering; C071447:ERCC1 protein, human; D004720:Endonucleases; D002945:Cisplatin